– Aiming for revolutionary innovation in next-generation medical care –
Masahiro Fujii, Associate Professor of Cardiovascular Surgery at Nippon Medical School Graduate School (Chief of the Department of Cardiovascular Surgery at Chiba Hokuso Hospital), and Tamabio Co., Ltd. have signed a joint research agreement to develop and analyze regenerative medical devices and treatment methods made by ion irradiation of synthetic materials. Tissue repair in the heart is an important issue, as no effective treatment has been established to date. The synthetic biomembrane developed by Tamabio has biocompatibility, and it has been suggested that tissue repair may occur using it as a scaffold. The Department of Cardiovascular Surgery at Nippon Medical School Chiba Hokuso Hospital will begin research to analyze the effectiveness of PeriBeam®, a pericardial membrane prosthesis developed by Tamabio and approved for pharmaceutical use in Japan and the United States, for the treatment of myocardial infarction and heart failure, focusing on its tissue repair ability. We aim to develop an unprecedented and effective treatment method, and will work to contribute to the treatment of many patients.
[Full Announcement]
● Masahiro Fujii, Associate Professor of Cardiovascular Surgery at the Graduate School of Cardiovascular Surgery at Nippon Medical School (Chief of the Department of Cardiovascular Surgery at Chiba Hokuso Hospital), and Tamabio Co., Ltd. have signed a joint research agreement to develop and analyze regenerative treatment devices and treatment methods made by ion irradiation of synthetic materials.
● The Cardiovascular Surgery Department at Nippon Medical School Chiba Hokuso Hospital has contributed to local medical care by accumulating the results of many open-heart and aortic surgeries, including emergency surgeries. In addition, the adjacent research facility is working in a cutting-edge experimental environment, focusing particularly on the advancement of myocardial protection.
● The synthetic biomembrane developed by Tamabio has biocompatibility, and it has been suggested that tissue repair may occur using it as a scaffold. Tamabio’s pericardial membrane prosthesis “PeriBeam🄬” has already been approved by the Ministry of Health, Labor and Welfare in Japan and the United States FDA, and is widely used in cardiac surgery.
● Tissue repair in the heart is an important issue, as no effective treatment has been established so far. The Cardiovascular Surgery Department at Nippon Medical School Chiba Hokuso Hospital will focus on the tissue repair ability of PeriBeam and begin research to analyze its effectiveness in treating myocardial infarction and heart failure. We will work to contribute to the treatment of many patients, including the development of unprecedented effective treatments.
＜About Nippon Medical School＞
Nippon Medical School is a private medical school in Japan that was founded over 140 years ago. Its founding spirit is “Saving the poor and suffering from illness is the most important path for a doctor,” its academic motto is “Sacrificing oneself for the good of the people,” and its educational philosophy is “Devoting oneself to the greater good of the people.” It has produced over 10,000 clinicians, medical researchers, and medical administrators. Among these, the Research Management Center, established in January 2016 for the purpose of building and maintaining the research infrastructure of the entire school corporation, supports the construction of the infrastructure for industry-academia collaboration and research activities such as this joint research project. Nippon Medical School is equipped with joint research facilities, one of which is the Chiba Hokuso Hospital Laboratory, which consists of nucleic acid, protein, cell culture, pathology, and animal (P2) laboratories, and can conduct cell culture and animal experiments, flow cytometry, real-time PCR, and pathological tissue research. It regularly updates its equipment, including deep freezers, autoclaves, and centrifuges, to support researchers’ study.
<About TamaBio>
Established: April 2016 CEO: Tetsuya Nagao Business: Medical device manufacturing/Type 1 manufacturing and sales Development, manufacturing, and sales of Durabeam🄬 (Class IV highly controlled medical device, artificial dura mater) Development, manufacturing, and sales of Peribeam🄬 (Class IV highly controlled medical device, artificial pericardium prosthesis) Development, manufacturing, and sales of other synthetic artificial biomembranes Tama Bio was established in April 2016, with the practical foundational technology of special processing of polymer resins from the Institute of Physical and Chemical Research. Tama Bio has obtained manufacturing and sales approval (Class IV) from the Ministry of Health, Labor, and Welfare for the artificial dura mater “Durabeam🄬” and the artificial pericardium prosthesis “Peribeam®”, and has been approved for sale in the United States by the US Food and Drug Administration (FDA). Core patents have been obtained in Japan, the United States, the People’s Republic of China, etc. In addition, “Durabeam🄬” is sold domestically by Gunze Medical Co., Ltd. (Head office: Kita-ku, Osaka City, President: Shojiro Matsuda), a consolidated subsidiary of Gunze Co., Ltd. (Head office: Kita-ku, Osaka City, President: Toshiyasu Saguchi), and “Peribeam🄬” is sold domestically by JMS Co., Ltd. (Head office: Naka-ku, Hiroshima City, President: Ryuji Katsura). In addition to the artificial dura mater “Durabeam🄬” and the artificial pericardium “Peribeam🄬”, Tama Bio is promoting the development of artificial organs and regenerative medicine technologies in more critical and promising fields. Medical devices such as implants are being developed around the world as functional substitutes for patients’ lost organs, but in clinical settings, various adverse events such as postoperative infections, adhesions with self-tissues, and calcification due to long-term use are issues. Tama Bio products are highly biocompatible, and we will overcome these challenges through our processing technology and continue to work to deliver newly developed products to patients. The latest research suggests that the synthetic biomembrane developed by TamaBio has biocompatibility and may serve as a scaffold for tissue repair. TamaBio is also expanding internationally, obtaining pharmaceutical approval overseas and building international business partnerships. Through this joint research, the two companies aim to expand the results of their innovative medical technology not only domestically but around the world.
For further details, please contact:
Tetsuya Nagao／TamaBio Co.,Ltd. (ME in AI & Aerospace, Managing Director)
Registered (Tokyo) : A Class 1 Medical Devices Manufacturer & Seller
PMDA Approval (DuraBeam(r) and PeriBeam(r)) : Class IV Highly Managed Medical Equipment
Mobile +81 80 1196 3206 / Tel +81 422 53 5051 / FAX +81 422 38 5091
https://tamabio.com/en/
402 2-2-18 Sakai Musashino-shi Tokyo Japan 180-0022